Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Chronic Radiation Ulcer
Interventions: PEP-TISSEEL, TISSEEL Fibrin Sealant KIT; Combination Product · Drug
Lead sponsor: Rion Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fatigue, Energy
Interventions: Energy Placebo Control Form 1, Energy Active Study Product 1.1 Usage, Energy Active Study Product 1.2 Usage, Energy Placebo Control Form 2, Energy Active Study Product 2.1 Usage, Energy Placebo Control Form 3, Energy Active Study Product 3.1 Usage, Energy Placebo Control Form 4, Energy Active Study Product 4.1 Usage, Energy Active Study Product 4.2 Usage, Energy Active Study Product 4.3 Usage, Energy Placebo Control Form 5.1.0, Energy Active Study Product 5.1.1 Usage, Energy Placebo Control Form 5.3.0, Energy Active Study Product 5.3.1 Usage, Energy Active Study Product 5.3.2 Usage, Energy Placebo Control Form 5.2.0, Energy Active Study Product 5.2.1 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 5,543 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Type 2 Diabetes, Cardiovascular Disease
Interventions: TAK-875, TAK-875 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 3,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 218
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more

Conditions: Vitreo-Retinal Surgery
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone; Drug
Lead sponsor: Patrick R. Oellers, MD; Network
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Liverpool, New York

Conditions: Chronic Constipation, Functional Constipation
Interventions: Placebo Capsule, YKP10811 Drug Product Capsule; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Schizophrenia
Interventions: Ziprasidone, Olanzapine, Placebo Comparator; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more

Conditions: Acute Postoperative Pain, Bunionectomy
Interventions: ACP-044 Dose A, ACP-044 Dose B, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anaheim, California • Pasadena, Maryland • San Antonio, Texas + 1 more

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions: Lipikar Balm AP; Drug
Lead sponsor: Cosmetique Active International; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Canton, Michigan • Fort Gratiot, Michigan

Conditions: Infection Secondary to Surgical Procedure
Interventions: ALT005 Ophthalmic Prep Solution, saline control, Betadine ophthalmic prep solution; Drug · Other
Lead sponsor: Altacor Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Caries
Interventions: 0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control); Drug
Lead sponsor: Domenick Zero; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Angelman Syndrome
Interventions: Levodopa, Placebo Oral Capsule; Drug
Lead sponsor: Wen-Hann Tan; Other
Eligibility: 4 Years to 12 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: San Diego, California • San Francisco, California • Boston, Massachusetts + 4 more

Conditions: Postoperative Pain
Interventions: HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more

Conditions: Body Odor
Interventions: NOBO postbiotic, Placebo; Other
Lead sponsor: Kingdom; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Dental Caries
Interventions: Ferumoxytol/Hydrogen peroxide, Hydrogen Peroxide, Water; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Indianapolis, Indiana • Philadelphia, Pennsylvania

Conditions: Overactive Bladder
Interventions: vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 191
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more

Conditions: Urinary Tract Infections in Children
Interventions: PedSCath Pediatric Urinary Catheter, Standard of Care; Device
Lead sponsor: Big Blue Biotech, Inc.; Industry
Eligibility: Up to 3 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Gainesville, Florida • Chicago, Illinois • Maywood, Illinois

Conditions: Low Back Pain
Interventions: Hydromorphone ER, Sugar pill; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC); Drug · Other
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Maimi, Florida

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Josef Stehlik; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Environmental Exposure, PFAS Exposure
Interventions: Streptococcus salivarius 46-SL1, Placebo; Dietary Supplement
Lead sponsor: Cambiotics ApS; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions: Sigvotatug Vedotin, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 85
States / cities: Fairbanks, Alaska • Fullerton, California • Golden, Colorado + 57 more

Search by objective public record fields.

Study to Evaluate the Safety, Tolerability, and Efficacy of PEP-TISSEEL in Subjects With Chronic Radiation Ulcer

Radicle Energy 24: A Study of Health and Wellness Products on Fatigue and Related Health Outcomes

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers

Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model

A Trial of Levodopa in Angelman Syndrome

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

A Fourth Proof-of-Concept Study to Evaluate the Efficacy of NOBO, a Novel Postbiotic, in Controlling Axillary Odor in Healthy Adults

Evaluation of Anti-biofilm Effects of Ferumoxytol (Feraheme) Using an in Situ Biofilm Demineralization Model

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.